Your browser doesn't support javascript.
loading
Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys.
Al-Abri, Seif Salem; Al-Wahaibi, Adil; Al-Kindi, Hanan; Kurup, Padmamohan J; Al-Maqbali, Ali; Al-Mayahi, Zayid; Al-Tobi, Mohammed Hamed; Al-Katheri, Salim Habbash; Albusaidi, Sultan; Al-Sukaiti, Mahmood Humaid; Al Balushi, Ahmed Yar Mohammed; Abdelgadir, Iyad Omer; Al-Shehi, Nawal; Morkos, Essam; Al-Maani, Amal; Al-Rawahi, Bader; Alyaquobi, Fatma; Alqayoudhi, Abdullah; Al-Harthy, Khalid; Al-Khalili, Sulien; Al-Rashdi, Azza; Al-Shukri, Intisar; Al Ghafri, Thamra S; Al-Hashmi, Fatma; Al Jassasi, Saeed Mussalam; Alshaqsi, Nasser; Mitra, Nilanjan; Al Aamry, Humaid Suhail; Shah, Parag; Al Marbouai, Hanan Hassan; Al Araimi, Amany Hamed; Kair, Ismail Mohammed; Al Manji, Asim Mohammed; Almallak, Ahmed Said; Al Alawi, Fatma Khamis; Vaidya, Vidyanand; Muqeetullah, Muhammad; Alrashdi, Hanan; Al Jamoudi, Saud Said Nassir; Alshaqsi, Asila; Al Sharji, Abdullah; Al Shukeiri, Hamida; Al-Abri, Badr; Al-Rawahi, Sulaiman; Al-Lamki, Said H; Al-Manji, Abdulla; Al-Jardani, Amina.
Afiliación
  • Al-Abri SS; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman. Electronic address: salabri@gmail.com.
  • Al-Wahaibi A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Kindi H; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Kurup PJ; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Maqbali A; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Al-Mayahi Z; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Al-Tobi MH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Al-Katheri SH; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Albusaidi S; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al-Sukaiti MH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhahira Governorate, Ministry of Health, Ibri, Oman.
  • Al Balushi AYM; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Abdelgadir IO; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Al-Shehi N; Department of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman.
  • Morkos E; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Wusta Governorate, Ministry of Health, Haima, Oman.
  • Al-Maani A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rawahi B; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Alyaquobi F; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Alqayoudhi A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Harthy K; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Khalili S; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rashdi A; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Shukri I; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al Ghafri TS; Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Hashmi F; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Al Jassasi SM; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhahira Governorate, Ministry of Health, Ibri, Oman.
  • Alshaqsi N; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Mitra N; Department of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman.
  • Al Aamry HS; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Shah P; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al Marbouai HH; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Al Araimi AH; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Kair IM; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Al Manji AM; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Almallak AS; Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman.
  • Al Alawi FK; Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman.
  • Vaidya V; Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman.
  • Muqeetullah M; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
  • Alrashdi H; Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman.
  • Al Jamoudi SSN; Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman.
  • Alshaqsi A; Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman.
  • Al Sharji A; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al Shukeiri H; Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman.
  • Al-Abri B; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Rawahi S; Health Services, Petroleum Development Oman, Muscat, Oman.
  • Al-Lamki SH; Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman.
  • Al-Manji A; Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
  • Al-Jardani A; Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman.
Int J Infect Dis ; 112: 269-277, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34601146
ABSTRACT

OBJECTIVE:

To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic.

METHODS:

This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors.

RESULTS:

In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35).

CONCLUSION:

This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article